for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Obseva SA

OBSV.O

Latest Trade

7.38USD

Change

-0.30(-3.91%)

Volume

20,149

Today's Range

7.38

 - 

7.85

52 Week Range

7.14

 - 

17.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest News

Swiss stocks - Factors to watch on September 12

The Swiss blue-chip SMI was seen opening 0.6 percent higher at 10,156 points -- what would be a record -- on Thursday, according to premarket indications by bank Julius Baer.

BRIEF-ObsEva Announces New Composition Of Its Executive Committee

* OBSEVA ANNOUNCES NEW COMPOSITION OF ITS EXECUTIVE COMMITTEE

BRIEF-Obseva SA Files For Mixed Shelf Of Upto $250 Million

* OBSEVA SA FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2yHP55N) Further company coverage:

Swiss stocks - Factors to watch on Aug 7

The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,548 points on Wednesday, according to premarket indications by bank Julius Baer.

Swiss stocks - Factors to watch on July 18

Here are some of the main factors that may affect Swiss stocks on Thursday:

BRIEF-Obseva To Increase Issued Share Capital

* OBSEVA TO INCREASE ISSUED SHARE CAPITAL BY CREATING ADDITIONAL TREASURY SHARES

Swiss stocks - Factors to watch on July 1

The Swiss blue-chip SMI was seen opening 0.7 percent higher at 9,969 points on Monday, according to premarket indications by bank Julius Baer .

BRIEF-Obseva Appoints Dr. Elizabeth Garner As Chief Medical Officer

* OBSEVA APPOINTS INDUSTRY EXPERT AS CHIEF MEDICAL OFFICER TO FURTHER ADVANCE ITS PHASE 3 CLINICAL PROGRAMS

Swiss stocks - Factors to watch on June 19

The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,977 points on xxday, according to premarket indications by bank Julius Baer .

BRIEF-Obseva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting

* OBSEVA PROGRESSING TOWARD U.S. PHASE 3 TRIAL FOR NOLASIBAN IN IVF FOLLOWING RECENT FDA MEETING

Swiss stocks - Factors to watch on June 4

The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9,585 points on Tuesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on May 9

The Swiss blue-chip SMI was seen opening 0.3 percent lower at 9,595 points on Thursday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on Nov. 28

The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,925 points on Wednesday, according to premarket indications by bank Julius Baer.

Swiss stocks - Factors to watch on Oct. 10

The Swiss blue-chip SMI was seen opening 0.2 percent lower at 8,950 points on Wednesday, according to premarket indications by bank Julius Baer.

BRIEF-Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM

* PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING

Swiss stocks - Factors to watch on Oct. 3

The Swiss blue-chip SMI was seen opening little changed at 9,090 points on Wednesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on Aug 8

The Swiss blue-chip SMI was seen opening little changed at 9,198 points on Wednesday, according to premarket indications by bank Julius Baer .

Swiss stocks - Factors to watch on July 13

The Swiss blue-chip SMI was seen opening up 0.3 percent at 8,844 points on Friday, according to premarket indications by bank Julius Baer .

ObsEva plans Swiss listing; trading debut on July 13

ObsEva <OBSV.O>, a Switzerland-based drug development company, said on Friday it plans a secondary listing on the SIX Swiss Exchange in Zurich and trading debut on July 13, as the firm seeks to gain more visibility among European investors.

Swiss stocks - Factors to watch on July 6

The Swiss blue-chip SMI was seen opening 0.5 percent higher at 8,714 points on Friday, according to premarket indications by bank Julius Baer .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up